Sloan-kettering Institute for Cancer Research

Other

Sloan-kettering Institute

Roland Mertelsmann

Karl Welte

Janice L Gabrilove

Erich Platzer

Salvatore Venuta

Malcolm A Moore

Malcolm A S Moore

Thomas Boehm

Hendrik Veelken

Peter Kulmburg

Felicia Rosenthal

Albrecht Lindemann

Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5&#xd7;10U/mg protein.

Human pluripotent hematopoietic colony stimulating factor, method of production and use

Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.

Human pluripotent hematopoietic colony stimulating factor and cell line

Methods for preparing and using clonogenic fibroblasts and transfected

This invention provides a composition comprising a therapeutically effective amount of purified human interleukin-2 and a pharmaceutically acceptable carrier.

Highly purified interleukin-2 and method

Method of producing human pluripotent hematopoietic colony stimulating

Method of administering human pluripotent hematopoietic colony

Human pluripotent hematopoietic colony stimulating factor

Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH.sub.4).sub.2 SO.sub.4 -precipitation, ion-exchange chromatogr

Purified interleukin 2

Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal huma

Process for preparing purified interleukin-2

Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lympho

Uses of interleukin-2

Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH.sub.4).sub.2 SO.sub.4 -precipitation, ion-exchange chromatography, gel filtration and hydrophobic chromatography. hp IL-2 is free of pyrogens, B cell inducing factor, B cell growth factor, interferon, CSF, and thymocyte differentiating factor. Nature IL 2 produced in the absence of Daudi cells has a molecular weight of about 26,000 daltons as measured by gel filtration and yields IL 2 having two molecular weights of about 16,000 and 17,000 daltons after denaturation as measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IL 2 produced in the presence of Daudi cells shows a molecular weight of approximately 14,500 daltons as measured by both gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This highly purified IL 2 is shown to correct immunodeficiency states in vitro and in vivo, especially in human patients. It shows value in the treatment of AIDS and immunodeficiency resulting from chemotherpy of cancer, as well as transplantation disorders such as graft versus host disease.

Growing community of inventors

Mainz, Germany

Roland Mertelsmann